Result of AGM
Oxford Biomedica PLC announced that all resolutions were passed at its Annual General Meeting on May 7, 2026, with strong shareholder support. The adoption of the Annual Report and accounts received 99.98% of votes in favour, while the Directors' Remuneration Report passed with 88.51% approval. All director reappointments and the reappointment of PricewaterhouseCoopers LLP as auditors also received overwhelming support, with votes for ranging from 96.78% to 99.09% for director reappointments and 99.98% for auditor reappointment. Resolutions to authorise directors to allot shares and disapply pre-emption rights also passed with high percentages, indicating continued shareholder confidence.
Select text to share a quote on X · sign in to keep highlights & notes in your OXB notes
Oxford, UK - 07 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that all proposed resolutions were duly passed at its Annual General Meeting ("AGM"), held at 3 pm on 07 May 2026 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of AGM by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2026 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (05 May 2026) there were 120,920,518 ordinary shares of 50 pence each in issue, each carrying one vote per share.
| Resolutions | Votes For (incl. votes at the Chair's discretion) | % of votes cast | Votes Against | % of votes cast | Votes Withheld* | Total votes cast** | Result | |
|---|---|---|---|---|---|---|---|---|
| Ordinary resolutions | ||||||||
| 1 | To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2025, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports. | 88,022,096 | 99.98% | 14,253 | 0.02% | 149,975 | 88,036,349 | PASS |
| 2 | To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) set out at pages 90 to 112 of the Annual Report for the financial year ended 31 December 2025. | 77,910,043 | 88.51% | 10,114,321 | 11.49% | 161,960 | 88,024,364 | PASS |
| 3 | To reappoint Dr. Roch Doliveux as a Director of the Company. | 85,639,916 | 97.24% | 2,431,539 | 2.76% | 114,869 | 88,071,455 | PASS |
| 4 | To reappoint Dr. Frank Mathias as a Director of the Company. | 86,374,661 | 98.07% | 1,696,798 | 1.93% | 114,865 | 88,071,459 | PASS |
| 5 | To reappoint Peter Soelkner as a Director of the Company. | 85,669,982 | 97.27% | 2,401,339 | 2.73% | 115,003 | 88,071,321 | PASS |
| 6 | To reappoint Professor Dame Kay Davies as a Director of the Company. | 85,671,463 | 97.28% | 2,399,858 | 2.72% | 115,003 | 88,071,321 | PASS |
| 7 | To reappoint Colin Bond as a Director of the Company. | 87,273,801 | 99.09% | 797,520 | 0.91% | 115,003 | 88,071,321 | PASS |
| 8 | To reappoint Dr. Lucinda Crabtree as a Director of the Company. | 88,047,431 | 99.97% | 24,028 | 0.03% | 114,865 | 88,071,459 | PASS |
| 9 | To reappoint Laurence Espinasse as a Director of the Company. | 88,046,231 | 99.97% | 25,093 | 0.03% | 115,000 | 88,071,324 | PASS |
| 10 | To reappoint Namrata Patel as a Director of the Company. | 88,045,714 | 99.97% | 25,610 | 0.03% | 115,000 | 88,071,324 | PASS |
| 11 | To reappoint Dr. Heather Preston as a Director of the Company. | 85,236,452 | 96.78% | 2,834,872 | 3.22% | 115,000 | 88,071,324 | PASS |
| 12 | To reappoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the 2026 AGM until the conclusion of the next AGM of the Company at which the accounts are laid. | 88,052,667 | 99.98% | 17,899 | 0.02% | 115,758 | 88,070,566 | PASS |
| 13 | To authorise the Audit Committee for and on behalf of the Board to determine the auditors' remuneration. | 88,054,882 | 99.98% | 16,778 | 0.02% | 114,664 | 88,071,660 | PASS |
| 14 | To authorise the Directors to allot shares. | 87,589,834 | 99.46% | 478,537 | 0.54% | 117,953 | 88,068,371 | PASS |
| Special resolutions | ||||||||
| 15 | To authorise the Directors to disapply pre-emption rights. | 87,247,698 | 99.07% | 819,891 | 0.93% | 118,735 | 88,067,589 | PASS |
| 16 | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments. | 87,103,359 | 98.90% | 968,950 | 1.10% | 114,015 | 88,072,309 | PASS |
| 17 | To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice. | 87,482,967 | 99.33% | 590,744 | 0.67% | 112,613 | 88,073,711 | PASS |
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
** Total does not include withheld votes.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.